Tags

Type your tag names separated by a space and hit enter

Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.
Clin Lab. 2009; 55(3-4):144-52.CL

Abstract

Hyperphosphataemia, calcitriol deficency and secondary hyperparathyroidism (sHPT) are common complications in end-stage chronic kidney diseases (CKD). Fibroblast Growth Factor 23 (FGF-23) is a phosphaturic peptide, secreted by the osteoblast precursors, that also inhibits renal 1-alpha-hydroxylase activitiy and tubular phosphate reabsorption by the inhibition of sodium-dependant renal phosphate transport (Na-Pi-IIa). Consequences are a decreaese of serum 1,25 dihydroxyvitamin D3 and phosphaturia. Therefore, FGF-23 plays a role in hyperphosphataemia in association with CKD and may be involved in the pathogenesis of sHPT. Increased FGF-23 may contribute to maintaining a normal serum phoshpate level in face of a processing CKD, but if the creatinine clearance is reduced to lower than 30 ml/min the capacity of this regulative mechanism ends and hyperphosphataemia results. In our investigation of end-stage renal diseases markedly increased serum FGF-23, associated with hyperphosphataemia, phosphaturia and decreased serum calcitriol and sHPT, were found. Furthermore preanalytical testing for the stability of FGF-23 was performed by comparing samples which were stored at -20 degrees C with samples that have been stored for 6 days at +4 degrees C. The simultaneous investigation of serum and EDTA plasma FGF-23 certifies the advantage of EDTA plasma in subjects with an intact renal function.

Authors+Show Affiliations

Dept. of Internal Medicine, Hospital zum Hl. Geist, Teaching Hospital of the Heinrich Heine University Duesseldorf, Kempen, Germany. w.j.fassbender@krankenhaus-kempen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

19462937

Citation

Fassbender, W J., et al. "Evaluation of Human Fibroblast Growth Factor 23 (FGF-23) C-terminal and Intact Enzyme-linked Immunosorbent-assays in End-stage Renal Disease Patients." Clinical Laboratory, vol. 55, no. 3-4, 2009, pp. 144-52.
Fassbender WJ, Brandenburg V, Schmitz S, et al. Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clin Lab. 2009;55(3-4):144-52.
Fassbender, W. J., Brandenburg, V., Schmitz, S., Sandig, D., Simon, S. A., Windolf, J., & Stumpf, U. C. (2009). Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clinical Laboratory, 55(3-4), 144-52.
Fassbender WJ, et al. Evaluation of Human Fibroblast Growth Factor 23 (FGF-23) C-terminal and Intact Enzyme-linked Immunosorbent-assays in End-stage Renal Disease Patients. Clin Lab. 2009;55(3-4):144-52. PubMed PMID: 19462937.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. AU - Fassbender,W J, AU - Brandenburg,V, AU - Schmitz,S, AU - Sandig,D, AU - Simon,S A, AU - Windolf,J, AU - Stumpf,U C, PY - 2009/5/26/entrez PY - 2009/5/26/pubmed PY - 2009/6/19/medline SP - 144 EP - 52 JF - Clinical laboratory JO - Clin Lab VL - 55 IS - 3-4 N2 - Hyperphosphataemia, calcitriol deficency and secondary hyperparathyroidism (sHPT) are common complications in end-stage chronic kidney diseases (CKD). Fibroblast Growth Factor 23 (FGF-23) is a phosphaturic peptide, secreted by the osteoblast precursors, that also inhibits renal 1-alpha-hydroxylase activitiy and tubular phosphate reabsorption by the inhibition of sodium-dependant renal phosphate transport (Na-Pi-IIa). Consequences are a decreaese of serum 1,25 dihydroxyvitamin D3 and phosphaturia. Therefore, FGF-23 plays a role in hyperphosphataemia in association with CKD and may be involved in the pathogenesis of sHPT. Increased FGF-23 may contribute to maintaining a normal serum phoshpate level in face of a processing CKD, but if the creatinine clearance is reduced to lower than 30 ml/min the capacity of this regulative mechanism ends and hyperphosphataemia results. In our investigation of end-stage renal diseases markedly increased serum FGF-23, associated with hyperphosphataemia, phosphaturia and decreased serum calcitriol and sHPT, were found. Furthermore preanalytical testing for the stability of FGF-23 was performed by comparing samples which were stored at -20 degrees C with samples that have been stored for 6 days at +4 degrees C. The simultaneous investigation of serum and EDTA plasma FGF-23 certifies the advantage of EDTA plasma in subjects with an intact renal function. SN - 1433-6510 UR - https://www.unboundmedicine.com/medline/citation/19462937/Evaluation_of_human_fibroblast_growth_factor_23__FGF_23__C_terminal_and_intact_enzyme_linked_immunosorbent_assays_in_end_stage_renal_disease_patients_ L2 - https://medlineplus.gov/kidneyfailure.html DB - PRIME DP - Unbound Medicine ER -